Es Oxali 50 Injection
Marketer
Esperer Bioresearch Pvt Ltd
Salt Composition
Oxaliplatin (50mg)
Overview Es Oxali 50 Injection
Oxaliplatin 50 Injection treats colorectal cancer by inhibiting or reducing the proliferation of cancerous cells. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician and may vary. Adhere strictly to prescribed instructions; improper usage or overdose can lead to severe adverse reactions. Therapeutic effects might not be apparent for weeks or months; discontinue only under medical guidance. Common side effects include nausea, fatigue, vomiting, and diarrhea. This medication can decrease blood cell counts, increasing infection risk. Severe allergic reactions, signaled by mouth sores, rash, itching, or breathing difficulties, necessitate immediate medical attention. Regular blood tests monitoring blood cell counts, cardiac function, liver health, and uric acid levels are essential. Prior to treatment, disclose any pre-existing heart, liver, or kidney conditions, and all current medications, including antibiotics, as interactions are possible. This injection is contraindicated during pregnancy and breastfeeding. It may cause male infertility; sperm preservation should be discussed with a doctor. Due to potential dizziness, avoid driving post-injection.
Uses of Es Oxali 50 Injection
Colorectal cancer
Major Benefits of Es Oxali 50 Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Es Oxali 50 Injection:
- Nausea
- Fatigue
- Anemia (low number of red blood cells)
- Vomiting
- Diarrhea
- Decreased white blood cell count (neutrophils)
- Low blood platelets
- Increased liver enzymes
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Stomatitis (Inflammation of the mouth)
How to use Es Oxali 50 Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Es Oxali 50 Injection works:
Es Oxali 50 Injection is an antineoplastic agent. Its mechanism of action involves disrupting the genetic structure (DNA and RNA) of cancerous cells, thereby inhibiting their proliferation.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Es Oxali 50 Injection may pose safety risks; physician consultation is advised.
PregnancyCONSULT YOUR DOCTOR
Administering Es Oxali 50 Injection to pregnant individuals is contraindicated due to established fetal risks. In exceptional, life-threatening circumstances, a physician might consider its use only when the potential benefits outweigh the hazards. Medical advice is essential.
Breast feedingUNSAFE
Administration of Es Oxali 50 Injection is contraindicated while breastfeeding due to potential infant toxicity.
DrivingUNSAFE
Oxaliplatin injections, such as Es Oxali 50, can produce adverse reactions potentially impairing driving ability. Treatment with oxaliplatin may increase the likelihood of dizziness, nausea, vomiting, and other neurological issues impacting gait, thus affecting driving safety.
KidneyCAUTION
Es Oxali 50 Injection requires careful administration to individuals with severely impaired renal function. Dosage modification of Es Oxali 50 Injection might be necessary in such cases. Physician consultation is advised. Data regarding Es Oxali 50 Injection use in this patient population is limited. Dosage alteration isn't suggested for patients exhibiting mild to moderate kidney impairment.
LiverCAUTION
Es Oxali 50 Injection requires careful administration in individuals with hepatic impairment. Dosage modification of Es Oxali 50 Injection may be necessary. Physician consultation is advised.
What if you forget to take Es Oxali 50 Injection :
Should you forget a scheduled dose of Es Oxali 50 Injection, seek medical advice.
Facts to Know About Es Oxali 50 Injection
| Label | Value |
|---|---|
| Chemical Classification | Platinum Equivalents |
| Developing Habits | No. |
| Treatment Category | Cancer Treatments |
| Actions | Platinum-based anticancer agents |
3,018 People bought this recently